Department of Pharmacology and Therapeutics, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Sci Rep. 2023 Feb 9;13(1):2280. doi: 10.1038/s41598-023-29332-2.
Off-target mutagenesis of CRISPR/Cas systems must be solved to facilitate safe gene therapy. Here, we report a novel approach, termed "PROTECTOR", to shield known off-target sites by directing the binding of an orthologous nuclease-dead Cas protein to the off-target site to sterically interfere with Cas activity. We show that this method reduces off-target mutation rates of two well-studied guide RNAs without compromising on-target activity and that it can be used in combination with high-fidelity Cas enzymes to further reduce off-target editing. This expands the suite of off-target mitigation strategies and offers an ability to protect off-target sites even when their sequences are fully identical to target sites.
为了促进安全的基因治疗,必须解决 CRISPR/Cas 系统的脱靶诱变问题。在这里,我们报告了一种新方法,称为“PROTECTOR”,通过指导同源核酸酶失活 Cas 蛋白与脱靶位点结合来屏蔽已知的脱靶位点,从而在空间上干扰 Cas 活性。我们表明,该方法可以降低两种经过充分研究的向导 RNA 的脱靶突变率,而不会影响靶标活性,并且可以与高保真 Cas 酶结合使用,以进一步降低脱靶编辑。这扩展了脱靶缓解策略套件,并提供了保护脱靶位点的能力,即使它们的序列与靶位点完全相同。